Experimental virus therapy takes on advanced cancers in first human trial

NCT ID NCT06444815

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VET3-TGI (a modified virus that targets and kills cancer cells) and atezolizumab (an immunotherapy drug)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) first-in-human trial with only 60 participants, so safety and effectiveness are not yet known. The virus may cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Mary Crowley Cancer Research

    RECRUITING

    Dallas, Texas, 75230, United States

    Contact Email: •••••@•••••

  • UC Irvine Health

    RECRUITING

    Orange, California, 92868, United States

  • UPMC- Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • USC/Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.